The epidemiology of FXTAS
The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS), Page: 17-30
2010
- 7Citations
- 3Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The prevalence of the FMR1 premutation ranges from 1/116 to 1/259 in women and from 1/251 to 1/1,250 in men. Population studies investigating the prevalence of FXTAS in the general population have not been conducted due to the rarity of the disorder. The prevalence of FXTAS is estimated to be 1/4,000 in men over the age of 55, due to age-dependent penetrance. The prevalence in women is thought to be much lower, at approximately 1/7,800, because of the protection of the second X chromosome. Many screening studies have been conducted in movement disorder populations, attempting to ascertain undiagnosed FXTAS cases and premutation expansions. These studies have yielded low rates, with a rate of 1.3% in cerebellar ataxia patients, <1% in parkinsonian disorders, such as Parkinson disease and multiple system atrophy, and 0% in essential tremor. Screening studies vary widely in the type of patients included, both in ethnicity and in gender. Wider inclusion criteria for screening should increase the rates of ascertainment of both FXTAS and premutation expansions in future studies.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79959990892&origin=inward; http://dx.doi.org/10.1007/978-1-4419-5805-1_2; http://link.springer.com/10.1007/978-1-4419-5805-1_2; http://link.springer.com/content/pdf/10.1007/978-1-4419-5805-1_2; https://dx.doi.org/10.1007/978-1-4419-5805-1_2; https://link.springer.com/chapter/10.1007/978-1-4419-5805-1_2
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know